EPHB4 and survival of colorectal cancer patients

Cancer Research

Volumn 66, Issue 18, 2006, Pages 8943-8948

  Davalos, Veronica ^a   Dopeso, Higinio ^a   Castaño, Julio ^a   Wilson, Andrew J ^c   Vilardell, Felip ^b   Romero Gimenez, Jordi ^a   Espín, Eloy ^a   Armengol, Manel ^a   Capella, Gabriel ^b   Mariadason, John M ^c   Aaltonen, Lauri A ^d   Schwartz Jr , Simo ^a   Arango, Diego ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c ALBERT EINSTEIN CANCER CENTER   (United States)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN RECEPTOR B4;

ARTICLE; CANCER SURVIVAL; CHILD; CLONOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METHYLATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; STAINING; TISSUE MICROARRAY;

CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA METHYLATION; DOWN-REGULATION; GENES, TUMOR SUPPRESSOR; HT29 CELLS; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROMOTER REGIONS (GENETICS); PROMOTER REGIONS, GENETIC; RECEPTOR, EPHB4; RISK FACTORS;

EID: 33749468973     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4640     Document Type: Article

References (25)

1. Xia G, Kumar SR, Stein JP, et al. EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene 2005;25:769-80.
2. Xia G, Kumar SR, Masood R, et al. EphB4 expression and biological significance in prostate cancer. Cancer Res 2005;65:4623-32.
3. Berclaz G, Andres AC, Albrecht D, et al. Expression of the receptor protein tyrosine kinase myk-1/htk in normal and malignant mammary epithelium. Biochem Biophys Res Commun 1996;226:869-75.
4. Gerety SS, Wang HU, Chen ZF, Anderson DJ. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 1999;4:403-14.
5. Henkemeyer M, Orioli D, Henderson JT, et al. Nuk controls pathfinding of commissural axons in the mammalian central nervous system. Cell 1996;86:35-46.
6. Holmberg J, Genander M, Halford MM, et al. EphB receptors coordinate migration and proliferation in the intestinal stem cell niche. Cell 2006;125:1151-63.
7. Batlle E, Henderson JT, Beghtel H, et al. β-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 2002;111:251-63.
8. Batlle E, Bacani J, Begthel H, et al. EphB receptor activity suppresses colorectal cancer progression. Nature 2005;435:1126-30.
9. Mariadason JM, Arango D, Shi Q, et al. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 2003;63:8791-812.
10. Arango D, Mariadason JM, Willson AJ, et al. c-Myc overexpression sensitizes colon cancer cells to camptothecin-induced apoptosis. Br J Cancer 2003;89:1757-65.
11. Arango D, Laiho P, Kokko A, et al. Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer. Gastroenterology 2005;129:874-84.
12. Berclaz G, Karamitopoulou E, Mazzucchelli L, et al. Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma. Ann Oncol 2003;14:220-6.
13. Alazzouzi H, Alhopuro P, Salovaara R, et al. SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res 2005;11:2606-11.
14. Maniatis T, Fritsch EF, Sambrook J. Molecular cloning: a laboratory manual. Cold Spring Harbor (NY): CSH Laboratory Press; 1989.
15. Alazzouzi H, Davalos V, Kokko A, et al. Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Res 2005;65:10170-3.
16. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-6.
17. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002;18:1427-31.
18. Noren NK, Lu M, Freeman AL, Koolpe M, Pasquale EB. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci U S A 2004;101:5583-8.
19. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 2000;19:6043-52.
20. Wang J, Kataoka H, Suzuki M, et al. Downregulation of EphA7 by hypermethylation in colorectal cancer. Oncogene 2005;24:5637-47.
21. Liu W, Jung YD, Ahmad SA, et al. Effects of over-expression of ephrin-B2 on tumour growth in human colorectal cancer. Br J Cancer 2004;90:1620-6.
22. Kumar SR, Singh J, Xia G, et al. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol 2006;169:279-93.
23. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457-63.
24. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103:1635-40.
25. Jubb AM, Zhong F, Bheddah S, et al. EphB2 is a prognostic factor in colorectal cancer. Clin Cancer Res 2005;11:5181-7.